Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-87562761 · 1 trial · 1 indication
DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity or hematologic toxicity.
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Number of participants with clinically significant abnormal laboratory values (hematology or chemistry) will be reported.
| Arm | Type | Description |
|---|---|---|
| JNJ-87562761 | EXPERIMENTAL | Participants will receive JNJ-87562761 during the Part 1 (Dose escalation) to determine the recommended phase 2 dose (RP2D) regimen(s). The dose will be escalated sequentially until the RP2D regimen(s) have been identified. In Part 2 (Dose expansion) participants will receive JNJ-87562761 at the RP2D regimen(s) determined in Part 1. |
| Name | Type | Description |
|---|---|---|
| JNJ-87562761 | DRUG | JNJ-87562761 will be administered. |
Inclusion Criteria: * Relapsed, refractory multiple myeloma with measurable disease defined as: (a) Serum monoclonal paraprotein (M-protein) level greater than (\>)0.5 grams per deciliter (g/dL); or (b) Urine M-protein level \>200 milligrams per 24 hours (mg/24 hours); or (c) Light chain multiple m...
Top 20 of 25 competitors
JNJ-87562761 is an investigational small molecule being developed for the treatment of relapsed or refractory multiple myeloma, a type of blood cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
JNJ-87562761 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma.
JNJ-87562761 is in Phase 1 clinical development. It is an investigational drug being studied in a single active clinical trial for relapsed or refractory multiple myeloma. The drug has not yet received regulatory approval and remains in the early stages of clinical testing.
JNJ-87562761 is being studied in clinical trial NCT06604715, titled 'A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma.' This Phase 1 trial is active but not recruiting, with an enrollment of 17 participants across Canada, South Korea, Spain, and Taiwan.
JNJ-87562761 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for relapsed or refractory multiple myeloma. The drug is being studied in an active clinical trial and has not yet completed the clinical development process required for regulatory approval.